Tara K. Iyer, MD

Articles

Positioning NK Receptor Antagonism in the Vasomotor Symptoms Treatment Landscape

December 10, 2025

Panelists discuss how NK receptor antagonists can be strategically positioned as core nonhormonal options within the broader VMS treatment landscape.

Beyond Vasomotor Symptoms: The Potential Role of NK Receptor Antagonism in Mood and Sleep

December 10, 2025

Panelists discuss how NK receptor antagonism may improve mood and sleep quality, linking thermoregulation with broader emotional and cognitive health benefits.

Exploring the Broader Therapeutic Potential of NK1 Receptor Antagonists Beyond Vasomotor Symptoms

December 03, 2025

Panelists discuss how NK1 receptor antagonists show promise beyond VMS, suggesting wider therapeutic potential across neurological and systemic conditions.

Evaluating the Rapid Onset of Vasomotor Symptom Improvement and Safety Profiles of NK Receptor Antagonists

December 03, 2025

Panelists discuss how NK receptor antagonists deliver fast symptom relief with strong safety profiles, improving adherence and clinical confidence in their use.

Efficacy and Safety of Elinzanetant in Vasomotor Symptoms in Women With Breast Cancer Receiving Endocrine Therapy

November 26, 2025

Panelists discuss how elinzanetant offers a safe, effective nonhormonal option for managing VMS in women receiving endocrine therapy for breast cancer.

Efficacy and Safety of Elinzanetant in Vasomotor Symptoms in Menopause

November 26, 2025

Panelists discuss how elinzanetant demonstrates strong efficacy and safety across trials, reinforcing neurokinin modulation as a viable core treatment for VMS.

Dual NK3/NK1 Receptor Antagonism for Vasomotor Symptoms

November 19, 2025

Panelists discuss how dual NK3/NK1 receptor antagonism may expand therapeutic benefits by targeting multiple neural pathways involved in VMS and mood regulation.

Managing Vasomotor Symptoms With NK3 Receptor Antagonism

November 19, 2025

Panelists discuss how NK3 receptor antagonism through fezolinetant offers effective, rapid relief from VMS with a strong safety profile and nonhormonal benefits.

NK Receptor Antagonism as Therapeutic Strategy for Vasomotor Symptoms

November 12, 2025

Panelists discuss how NK receptor antagonism provides a targeted, nonhormonal strategy that addresses the physiological root of vasomotor symptoms.

Unmet Needs in Managing Vasomotor Symptoms in Menopause

November 12, 2025

Panelists discuss how limited treatment options and systemic barriers underscore the urgent need for accessible, targeted therapies for vasomotor symptoms.